Cancer patients who receive chemotherapy as part of their treatment may be at increased risk for cardiotoxicity and vascular disease. New cancer therapies may interfere with normal heart and vascular function. Specialists trained in cardio-oncology can detect these adverse reactions at an early stage and develop personalized treatment plans to avoid serious cardiovascular complications.
UR Medicine Heart & Vascular is collaborating with the Wilmot Cancer Institute to offer our unique Cardio-Oncology Program—the only one of its kind in Upstate New York.
Led by Eugene Storozynsky, MD, PhD, a cardiologist who specializes in heart failure and transplantation, the program identifies patients who have cancer and may be at an increased risk for chemotherapy-induced cardiotoxicity, with the goal of minimizing this reaction to chemotherapy.
We use innovative imaging techniques such as strain echocardiography, cardiac MRI, angiography, and associated endomyocardial biopsy to identify patients and address their risk factors to minimize potential cardiotoxicity. And, for those who have already developed cardiotoxicity, we’ll treat it.
Our team is working on new solutions for people who have heart damage from chemotherapy. In this nationwide study, a pacemaker-like device restored heart function in a group of cancer survivors. Researchers from URMC led the nationwide study, which was reported in the Journal of the American Medical Association.Read More
If you or a loved one is a cancer patient receiving chemotherapy and you have concerns about cardiotoxicity, contact the UR Medicine Cardio-Oncology Program at (585) 275-2475.